Sterling Biotech Limited announced audited earnings results for the fourth quarter and year ended March 31, 2017. For the quarter, the company reported net sales of INR 985.152 million compared with INR 1,209.033 million for the same period a year ago. Loss from operation before other income, finance costs was INR 596.988 million compared with loss of INR 490.287 million for the same period a year ago. Loss from ordinary activities before tax was INR 1,576.895 million compared with INR loss of 1,319.269 million for the same period a year ago. Net loss was INR 1,122.395 million or loss of INR 2.59 per diluted share before and after extraordinary items compared with INR 862.669 million or loss of INR 1.99 per diluted share before and after extraordinary items for the same period a year ago. For the year end, the company reported net sales of INR 4,001.895 million. Loss from operation before other income, finance costs was INR 2,469.972 million. Loss from ordinary activities before tax was INR 6,167.949 million. Net loss was INR 4,124.549 million or loss of INR 9.52 per diluted share before and after extraordinary items.